Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Vicente Morales‐Oyarvide

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7417-5626; OpenAlex author ID A5084172082, A5086787481. Sources: OpenAlex.

Their work

Papers
24 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
104
Papers, trials and grants by year

2016: 2 papers · 2017: 6 papers · 2018: 5 papers · 2019: 4 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers

Papers 24

  1. Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Ass… Co-author DOI 10.1097/sla.0000000000005313↗
  2. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  3. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  4. Prediagnostic Inflammation and Pancreatic Cancer Survival. First author DOI 10.1093/jnci/djab040↗
  5. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  6. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  7. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  8. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  9. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  10. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. Co-author DOI 10.1158/1055-9965.epi-19-0370↗
  11. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-19-0577↗
  12. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  13. Statin use and pancreatic cancer risk in two prospective cohort studies. Co-author DOI 10.1007/s00535-018-1430-x↗
  14. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.022↗
  15. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Co-author DOI 10.1038/s41424-018-0008-5↗
  16. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studie… Co-author DOI 10.1053/j.gastro.2017.12.001↗
  17. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  18. Critical role for arginase 2 in obesity-associated pancreatic cancer. Co-author DOI 10.1038/s41467-017-00331-y↗
  19. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarc… Co-author DOI 10.1097/sla.0000000000001763↗
  20. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-312510↗
  21. Cigarette Smoking and Pancreatic Cancer Survival. First author DOI 10.1200/jco.2016.71.2026↗
  22. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. First author DOI 10.1371/journal.pone.0182855↗
  23. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Co-author DOI 10.1158/0008-5472.can-16-1699↗
  24. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2015.66.3005↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 21 shared papers, 2016–2023 · strength 1.47
  2. Chen Yuan · 19 shared papers, 2016–2023 · strength 1.35
  3. Kimmie Ng · 16 shared papers, 2016–2022 · strength 1.06
  4. Charles S. Fuchs · 16 shared papers, 2016–2021 · strength 1.04
  5. Douglas Adam Rubinson · 14 shared papers, 2016–2023 · strength 1.01
  6. Ana Babić · 15 shared papers, 2016–2021 · strength 0.95
  7. Jonathan Andrew Nowak · 12 shared papers, 2017–2023 · strength 0.92
  8. Natalia I. Khalaf · 10 shared papers, 2017–2021 · strength 0.68
  9. Edward L. Giovannucci · 10 shared papers, 2016–2021 · strength 0.65
  10. Peter Kraft · 10 shared papers, 2016–2021 · strength 0.65
  11. Thomas E. Clancy · 8 shared papers, 2017–2023 · strength 0.63
  12. Richard Francis Dunne · 8 shared papers, 2017–2023 · strength 0.61
  13. Albert C. Koong · 7 shared papers, 2017–2023 · strength 0.55
  14. Margaret M. Kozak · 7 shared papers, 2017–2023 · strength 0.55
  15. Daniel Tandel Chang · 7 shared papers, 2017–2023 · strength 0.55
  16. Aram F. Hezel · 7 shared papers, 2017–2023 · strength 0.55
  17. Kimberly J. Perez · 6 shared papers, 2019–2023 · strength 0.54
  18. Andrew J. Aguirre · 6 shared papers, 2018–2023 · strength 0.50
  19. Zhi Rong Qian · 9 shared papers, 2016–2019 · strength 0.49
  20. Andressa Dias Costa · 5 shared papers, 2020–2023 · strength 0.48
  21. David C. Linehan · 6 shared papers, 2017–2023 · strength 0.47
  22. JoAnn E. Manson · 7 shared papers, 2016–2021 · strength 0.43
  23. Tsuyoshi Hamada · 6 shared papers, 2018–2020 · strength 0.43
  24. Sara A. Väyrynen · 4 shared papers, 2021–2023 · strength 0.40
  25. Jiping Wang · 3 shared papers, 2021–2023 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.